Two entities that seem like they should be on the same page a coalition of environmental groups and a plant-based food company are at odds.
And the flash point is a veggie burger.
Impossible Foods is facing scrutiny about the safety of a key ingredient in its trademark Impossible Burger, commonly known as the veggie burger that bleeds.
The controversy arose when theNew York Timespublished an article highlightingcorrespondencebetween the FDA and Impossible Foods that environmental groups say indicates that the protein had not met the agencys approval before going to market about a year ago.
Currently our FDA, EPA and USDA regulations are falling behind the very quickly moving development of new technologies, and one of the ways that our regulatory agencies are falling behind is they are not assessing the process of genetically engineering these ingredients, said Dana Perls of Friends of the Earth, one of the groups that raised concerns about Impossible Foods safety testing.
[Read the GLPs profile on Friends of the Earth.]
[The companys CEO and founder, Patrick Brown] said the groups objections are more about the use of biotechnology than the product itself.
The vast majority of their effort is an antiscience, anti-GMO crusade, Brown said. Their strategy has tended to be to try to effectively take down any company that is using biotechnology by whatever means they can come up with.
[Editors note: Below is a letter by Impossible Burger CEO and founder Patrick Brown, republished in full with permission from the company.]
The New York Times published an Aug. 8 article falsely implying that Impossible Foods is trying to evade US Food and Drug Administration regulations and putting consumers at risk by selling a product (the Impossible Burger) containing soy leghemoglobin. The article was chock full of factual errors and misrepresentations and was instigated by an extremist anti-science group with the deliberate intention of damaging our reputation.
Heres the truth:
The greatest threat the world faces today is the enormously destructive impact that our use of animals as a food technology has on climate, water, wildlife and biodiversity, global food security and political stability. Although little known to the public and almost completely ignored by the news media, this threat is well recognized by environmental and climate scientists and organizations including the UN Environmental Program, the UN Food and Agriculture Organization, and the Union of Concerned Scientists, among many others. The problem is not going to be solved by asking that people give up, or even reduce, consumption of the animal-derived foods they love; the demand for meat, fish and dairy foods is growing even faster than the human population. Nothing is more important to the planet our children and future generations will inherit, or their quality of life, than finding a solution to this dilemma.
Thats why I founded Impossible Foods. Our singular mission is to enable the world to continue to enjoy the foods they love and increasingly demand, without catastrophic damage to the environment. Our strategy was simple: invent a better way to transform plants into delicious, nutritious, safe and affordable meat, fish and dairy foods that consumers love. Then let consumers choose. If we do our job right, the market will take care of the rest. Commitment to the health, nutrition and safety of our customers is an inseparable part of our mission; its at the heart of why we exist, embedded in our ethos and everything we do.
With support from investors who understand and believe in our mission, we built a team of scientists who have worked tirelessly on this problem, understanding meat what underlies its flavor, texture and all its physical properties far better than it was ever understood. One of many discoveries they made, perhaps the most important, is that a molecule called heme is what makes meat taste like meat. Without heme, you cant make meat that will satisfy the billions of people who love meat.
Heme is an iron-containing molecule thats essential for life on Earth. Its found in every living organism. Its the magic molecule that enables the cells in our bodies and in every living being on Earth to benefit from the oxygen in our atmosphere. Its the molecule that carries oxygen in our blood, makes our blood red and our lips pink. Because its in every plant and animal, humans have been eating heme every day since the first human walked on Earth. The reason that animal tissues (meat) tastes like meat and unlike any vegetable, is that animal tissues contain hundreds to thousands-fold more heme than plant tissues.
To accomplish our essential mission, we needed to find a safe way to produce heme without using animals. We used yeast cells, into which we introduced a plant gene encoding a protein called soy leghemoglobin thats naturally found in the roots of soy plants. The heme in the Impossible Burger is atom-for-atom identical to the heme found in meat, fish, plants and other foods. Soy leghemoglobin carries the heme molecule in the same way a very similar protein, myoglobin, carries heme in muscle tissue (meat). Myoglobin is just one of the thousands of different heme proteins we all consume safely in our diets every day.
The health and safety of our customers is our first priority. The foods in our diet and the molecules and ingredients they contain are by default presumed to be safe, but only a minuscule fraction have ever been scientifically tested for their safety. Although there was never a reason to suspect that soy leghemoglobin would pose any more risk than myoglobin, or any of the new proteins we encounter in our diet all the time, we started four years ago to do a deep scientific study of its safety, including any potential for toxicity or allergenicity. The data we collected and our analyses were documented and reviewed by three independent food-safety experts in toxicology, allergenicity and yeast. In 2014, this expert panel unanimously concluded based on all the evidence that the protein is generally recognized as safe (GRAS) for human consumption. This is the approach followed by thousands of food companies to meet the FDA requirement that foods be generally recognized as safe. But we did more.
There is no legal or regulatory requirement that a companys finding of GRAS be submitted to the FDA for review. And its frequently not done. In fact, a total of only 709 have been submitted since the GRAS Notification system was put in place almost 20 years ago in 1998. But we did it because we recognize and respect the value of the FDA as guardian of the safety of the American food supply, one of the safest in the world.
We wanted the FDA to review our GRAS determination, to have the added benefit of their expertise, and to assure consumers that our testing of leghemoglobin has passed the most rigorous scrutiny. After submitting our GRAS determination, the FDA reviewed it, and had some questions. To address them, we conducted additional tests. And the tests turned out just as we expected: no adverse effects in rats consuming leghemoglobin every day for a month at levels more than 200 times what an average American would consume if all the ground beef in their diet were the Impossible Burger, and very low risk of allergenicity. A panel of the worlds leading experts in food safety and allergenicity has reviewed the new data, as well as the data originally submitted.
The expert panel has again unanimously concluded that soy leghemoglobin is safe; it is GRAS.
Impossible Foods has always worked constructively with the FDA, whose role as guardian of food safety for the nation we deeply respect. We will be submitting the additional data, along with the expert panels analysis of it, to the FDA this month. And FDA will make Impossible Foodss submission hundreds of pages of safety and allergenicity test results and the expert analysis of those results publicly available on its web site soon thereafter. In addition, in an abundance of caution, we clearly label our product as containing potential allergens: wheat and soy also in compliance with federal regulations. Finally, restaurants where the Impossible Burger is sold also comply with federal regulations about labeling.
Impossible Foods is proud of the safety of its first product, the Impossible Burger, and is committed to the health and safety of our customers. Thats why weve gone far beyond merely complying with food safety regulations, and we always will. I am confident in saying that the Impossible Burger is the safest and most thoroughly safety-tested burger in history. In striking contrast, the alternative, animal-derived burger is one of the least safe and most inadequately tested foods on the market.
And were committed to solving the most urgent threat the world faces today: the use of animals in the food system. Since the small-scale launch of the Impossible Burger, with just 50,000 lbs sold to date (10 billion lbs of ground beef were sold in the same time period), and working with our great restaurant partners, the Impossible Burger has already had an outsized impact: weve had an overwhelmingly positive response from consumers, and weve reduced greenhouse gases emissions by the equivalent of removing 246 American cars from the road for a year, reduced the land footprint of meat production by an area half the size of New Yorks Central Park, saved as much fresh water as 50,000 average Americans drink in a year, and saved more than 100 cows from slaughter. We cant solve this problem unless people love our burger.
Impossible Foods intends to be the most open and transparent company in the world. We welcome every opportunity to answer questions from the public and media, and share our answers on our social media channels. Before deciding how you feel about Impossible Foods or the Impossible Burger, read our story and then decide for yourself.
Continue reading here:
Impossible Burger blowback: Will irrational fears of biotechnology block introduction of sustainable foods? - Genetic Literacy Project
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance - November 16th, 2024
- Department of Biotechnology Launches Webinar Series on Biomanufacturing and Biofoundry Initiative - IBG NEWS - November 16th, 2024
- Multimodal scanning of genetic variants with base and prime editing - Nature.com - November 16th, 2024
- NEW INITIATIVE BY THE ITALIAN EMBASSY IN WASHINGTON ON BIOTECHNOLOGY WITH THE MILKEN INSTITUTE AND LEADING RESEARCHERS AND INDUSTRY EXPERTS -... - November 16th, 2024
- Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at... - November 16th, 2024
- Albany State offers new Master of Science in Integrated Biotechnology program - The Albany Herald - November 16th, 2024
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Benzinga - November 16th, 2024
- iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business - Simply Wall St - November 16th, 2024
- PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks - November 16th, 2024
- We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative - Yahoo Finance - November 16th, 2024
- Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest - Simply Wall St - November 16th, 2024
- APHIS Announces Final Notice on Additional Exemptions for the Movement of Organisms Modified or Produced Through Genetic Engineering - USDA APHIS - November 16th, 2024
- Adaptimmune nears second approval for TCR-T therapy - European Biotechnology News - November 16th, 2024
- Lundbeck reports 18% revenue growth in third quarter - The Pharma Letter - November 16th, 2024
- BioNTech to boost oncology offering with buy of Biotheus - The Pharma Letter - November 16th, 2024
- Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance - November 16th, 2024
- WPI Receives Federal Funding to Address Anticipated Demand for Biology and Biotechnology Professionals and Educators - WPI News - November 3rd, 2024
- Jonathan Dinman to Direct the Institute for Bioscience and Biotechnology Research - College of Computer, Mathematical, and Natural Sciences - November 3rd, 2024
- PDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of "Buy" by Analysts - MarketBeat - November 3rd, 2024
- COP16, DSI mechanism for benefit sharing from the use of digital sequence information approved - Renewable Matter - November 3rd, 2024
- Artificial Intelligence in Biotechnology Market to Hit USD 7.75 Billion by 2029 with 19.1% CAGR | MarketsandMarkets - PR Newswire - November 3rd, 2024
- Axonis Therapeutics raises $115 million in Series A financing - The Pharma Letter - November 3rd, 2024
- Regeneron third-quarter 2024 earnings top expectations - The Pharma Letter - November 3rd, 2024
- AbbVie inks up to $1.4 billion deal with EvolveImmune - The Pharma Letter - November 3rd, 2024
- CEO and Chairman of the Executive Board - European Biotechnology News - November 3rd, 2024
- The transformative potential of biotechnology and AI in healthcare - The Armchair Trader - November 3rd, 2024
- U.S. Biotechnology And Pharmaceutical Services Outsourcing Market Size to Reach USD 16.68 Billion By 2033 - BioSpace - October 6th, 2024
- Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance - October 6th, 2024
- Resolution Therapeutics scores 63.5 million in series B round - The Pharma Letter - October 6th, 2024
- Wiregrass Institute for Biotechnology welcomes local military veteran from Southeast Health as its first computational biologist - AOL - October 6th, 2024
- Generating and characterizing a comprehensive panel of CHO cells glycosylation mutants for advancing glycobiology and biotechnology research -... - October 6th, 2024
- Sapience Therapeutics Announces Participation at the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum - PR Newswire - October 6th, 2024
- Spyre Therapeutics lures Abivax exec to be its CMO - The Pharma Letter - October 6th, 2024
- Convergence is AIxBio: AI and the Bioeconomy - OODA Loop - October 6th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - ABC News - September 13th, 2024
- Researchers, media engage to educate farmers on biotechnology - University World News - September 13th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - The Associated Press - September 13th, 2024
- Comer Delivers Remarks in Support of Bipartisan BIOSECURE Act - House Committee on Oversight and Reform | - September 13th, 2024
- Announcement of $2 Million for the University of Delaware to Advance Biotechnology - WGMD Radio - September 13th, 2024
- Thailand's Competitiveness Enhanced Through Advanced Biotechnology at Thailand LAB INTERNATIONAL 2024 - BSA bureau - September 13th, 2024
- Biotechnology company Amgen expands global reach with technology innovation center in Hyderabad, India - BioProcess Insider - September 13th, 2024
- Adam's Biotech Scorecard: Can iTeos and GSK solve TIGIT's troubles? - STAT - September 13th, 2024
- Cizzle Biotechnology Advancing Lung Cancer Detection from R&D to Application with Moffitt Cancer Centre (VIDEO) - DirectorsTalk Interviews - September 13th, 2024
- MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - Business Wire - September 13th, 2024
- MAIA Biotechnology Advances with Clinical Trials and Partnerships - TipRanks - September 13th, 2024
- Viridian Therapeutics reports positive results for veligrotug - The Pharma Letter - September 13th, 2024
- Chinese biotech firms refute US bill, stressing they have no access to Americans personal data - Global Times - September 13th, 2024
- Vir Biotechnology Enhances Portfolio with Sanofi Deal and Executive Appointments - TipRanks - September 13th, 2024
- Tesla BioHealing and Cell Biotechnology Partner to Advance Stem Cell Therapies - Vancity Buzz - September 13th, 2024
- Time to leverage intellectual property to drive innovation in seed and biotechnology sectors: Experts - The Times of India - May 5th, 2024
- Where Does Capricor Therapeutics Inc (CAPR) Stock Fall in the Biotechnology Field After It Has Risen 24.73% This Week? - InvestorsObserver - March 10th, 2024
- Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field After It Has Gained 12.41% This Week? - InvestorsObserver - February 18th, 2024
- Should Biotechnology Stock Axsome Therapeutics Inc (AXSM) Be in Your Portfolio Wednesday? - InvestorsObserver - February 18th, 2024
- Where Does Candel Therapeutics Inc (CADL) Stock Fall in the Biotechnology Field After It Has Gained 22.38% This Week? - InvestorsObserver - February 18th, 2024
- What is Biotechnology? Types and Applications - Iberdrola - January 25th, 2024
- Where Does Immunitybio Inc (IBRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.32% This Week? - InvestorsObserver - January 25th, 2024
- Can Sana Biotechnology Inc (SANA) Stock Rise to the Top of Healthcare Sector Monday? - InvestorsObserver - January 25th, 2024
- Should You Buy Sana Biotechnology Inc (SANA) Stock After it Has Fallen 15.41% in a Week? - InvestorsObserver - January 25th, 2024
- Where Does Tscan Therapeutics Inc (TCRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.81% This Week? - InvestorsObserver - January 25th, 2024
- Should Biotechnology Stock Mink Therapeutics Inc (INKT) Be in Your Portfolio Monday? - InvestorsObserver - May 9th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Has Risen 22.18% This Week? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Dermata Therapeutics Inc (DRMA) Be in Your Portfolio Thursday? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Tempest Therapeutics Inc (TPST) Be in Your Portfolio Wednesday? - InvestorsObserver - May 9th, 2023
- Biotechnology - Applications of biotechnology | Britannica - May 1st, 2023
- Where Does BioLine RX Ltd - ADR (BLRX) Stock Fall in the Biotechnology Field After It Is Down -3.67% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Apellis Pharmaceuticals Inc (APLS) Stock Fall in the Biotechnology Field After It Is Higher By 4.17% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Aldeyra Therapeutics Inc (ALDX) Stock Fall in the Biotechnology Field After It Is Lower By -11.45% This Week? - InvestorsObserver - May 1st, 2023
- Is Rain Oncology Inc (RAIN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - April 7th, 2023
- Does Sana Biotechnology Inc (SANA) Have What it Takes to be in Your Portfolio Tuesday? - InvestorsObserver - April 7th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Is Lower By -15.43% This Week? - InvestorsObserver - April 7th, 2023
- Where Does Protagonist Therapeutics Inc (PTGX) Stock Fall in the Biotechnology Field After It Has Risen 3.62% This Week? - InvestorsObserver - April 7th, 2023
- What is Biotechnology? Definition, Types and Applications | TechTarget - March 21st, 2023
- Where Does Novavax Inc (NVAX) Stock Fall in the Biotechnology Field After It Is Lower By -12.99% This Week? - InvestorsObserver - March 21st, 2023
- Should Biotechnology Stock Outlook Therapeutics Inc (OTLK) Be in Your Portfolio Thursday? - InvestorsObserver - March 21st, 2023
- SANA BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com - March 21st, 2023
- Where Does Revance Therapeutics Inc (RVNC) Stock Fall in the Biotechnology Field After It Is Lower By -2.17% This Week? - InvestorsObserver - March 5th, 2023
- Is TG Therapeutics Inc common stock (TGTX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 5th, 2023
- Where Does GT Biopharma Inc (GTBP) Stock Fall in the Biotechnology Field After It Is Down -20.73% This Week? - InvestorsObserver - March 5th, 2023
- Where Does Dyne Therapeutics Inc (DYN) Stock Fall in the Biotechnology Field After It Is Lower By -2.35% This Week? - InvestorsObserver - March 5th, 2023
- Is CytomX Therapeutics Inc (CTMX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - November 17th, 2022